Antibody glycosylation in autoimmune diseases.
Antibody glycosylation in autoimmune diseases.
复制标题
DOI：
10.1016/j.autrev.2021.102804
复制
发表时间：
2021-05
影响因子：
13.6
通讯作者：
Zhang W
中科院分区：
文献类型：
--
作者：
Zhou X;Motta F;Selmi C;Ridgway WM;Gershwin ME;Zhang W
免疫球蛋白（IG）的可结晶片段（Fc）区的糖基化对于调节抗体对炎症的作用是至关重要的。此外，抗体糖基化可诱导病理改变并最终促成自身免疫性疾病的发展。由于糖基化分析的进展，在自身免疫性疾病的背景下，可以获得更多关于IgG及其亚类结构的数据。在这篇综述中，我们重点介绍了自身免疫中IG糖基化的影响，描述了它如何调节免疫反应以及糖组谱如何用作疾病活动的生物标志物。抗体糖基化的分析证明了人类自身免疫性和慢性炎症性疾病的特异性特征，包括类风湿性关节炎、系统性红斑狼疮、炎症性肠病和自身免疫性肝病等。在同一种疾病中，不同的模式与疾病的严重程度和治疗方案有关。未来的研究可能会增加不同糖组谱的可用信息，并扩大其作为生物标志物和治疗靶点的潜在作用，最终有利于个体化方法。
The glycosylation of the fragment crystallizable (Fc) region of immunoglobulins (Ig) is critical for the modulation of antibody effects on inflammation. Moreover, antibody glycosylation may induce pathologic modifications and ultimately contribute to the development of autoimmune diseases. Thanks to progress in the analysis of glycosylation, more data are available on IgG and its subclass structures in the context of autoimmune diseases. In this review, we focused on the impact of Ig glycosylation in autoimmunity, describing how it modulates the immune response and how glycome profiles can be used as biomarkers of disease activity. The analysis of antibody glycosylation demonstrated specific features in human autoimmune and chronic inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease and autoimmune liver diseases, among others. Within the same disease, different patterns are associated with disease severity and treatment options. Future research may increase the information available on the distinct glycome profiles and expand their potential role as biomarkers and as targets for treatment, ultimately favoring an individualized approach.